In this single-center retrospective cohort, neoadjuvant-plus-adjuvant dabrafenib and trametinib was feasible, enabling timely surgery with manageable toxicities. Survival outcomes were comparable to adjuvant-only therapy, and pathological responses in the neoadjuvant cohort provide exploratory prognostic information.

10 days ago

Clinical • Retrospective data • Journal

BRAF (B-raf proto-oncogene)

BRAF V600E • BRAF V600 • BRAF V600K

Mekinist (trametinib) • Tafinlar (dabrafenib)

10d

Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer (clinicaltrials.gov)

P1, N=22, Active, not recruiting, National Cancer Institute (NCI) | N=85 --> 22 | Trial completion date: Jun 2026 --> Nov 2026 | Trial primary completion date: Jun 2026 --> Nov 2025

10 days ago

Enrollment change • Trial completion date • Trial primary completion date

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)

BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • BRAF V600K • KEAP1 mutation • NFE2L2 mutation

Guardant360® CDx • MSK-IMPACT

sapanisertib (CB-228) • telaglenastat (CB-839)

13d

Routine sequencing of BRAF exon 15 improves therapeutic stratification for metastatic melanoma. (PubMed, Am J Clin Pathol)

Next-generation sequencing is a sensitive platform for profiling BRAF exon 15 mutations that cannot be detected by other techniques. Our results support the routine sequencing of BRAF exon 15 to improve patient stratification for therapy.

13 days ago

Journal

BRAF (B-raf proto-oncogene)

BRAF V600E • BRAF V600K

24d

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer (clinicaltrials.gov)

P1, N=6, Recruiting, City of Hope Medical Center | Trial completion date: Oct 2025 --> Feb 2026 | Trial primary completion date: Oct 2025 --> Feb 2026

24 days ago

Trial completion date • Trial primary completion date

BRAF V600E • BRAF V600 • BRAF V600K

Mekinist (trametinib) • Tafinlar (dabrafenib)

Somatic gene variation profiles in geriatric and adult malignant melanoma patients. (PubMed, Front Oncol)

Delineating the distribution of somatic variations in geriatric MM cases holds significant importance in the development of healthcare policies. These data are the first reported findings from Türkiye.

1 month ago

Journal • BRCA Biomarker

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NF1 (Neurofibromin 1)

BRAF V600E • BRAF V600 • BRAF V600K

Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment (clinicaltrials.gov)

P1/2, N=58, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting

1 month ago

Enrollment closed

BRAF V600E • BRAF V600 • BRAF V600K • EZH2 mutation

Guardant360® CDx

Mekinist (trametinib) • Tafinlar (dabrafenib) • Tazverik (tazemetostat)

2ms

A Phase 1/2 Study of Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid Tumors (clinicaltrials.gov)

P1/2, N=144, Active, not recruiting, Deciphera Pharmaceuticals, LLC | Recruiting --> Active, not recruiting

2 months ago

Enrollment closed • First-in-human

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • NF1 (Neurofibromin 1)

BRAF V600E • KRAS mutation • KRAS G12C • NRAS mutation • BRAF V600 • BRAF V600K • KRAS G12

Mekinist (trametinib) • Lumakras (sotorasib) • Mektovi (binimetinib) • inlexisertib (DCC-3116)

2ms

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer (clinicaltrials.gov)

P2, N=19, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2025 --> Sep 2026

2 months ago

Trial completion date • Trial primary completion date

BRAF V600E • BRAF V600 • BRAF V600K

Mekinist (trametinib) • Tafinlar (dabrafenib) • spartalizumab (PDR001)

3ms

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations (clinicaltrials.gov)

P1, N=71, Suspended, JS InnoPharm, LLC | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Jun 2024 --> Dec 2025

3 months ago

Trial completion date • Trial primary completion date

MAP2K1 (Mitogen-activated protein kinase kinase 1) • NF1 (Neurofibromin 1) • RASA1 (RAS P21 Protein Activator 1)

BRAF V600E • BRAF V600K

Tafinlar (dabrafenib) • JSI-1187

3ms

Adjuvant anti-PD-1 therapy improves melanoma-specific survival in stage IIIC-IV melanoma patients with high tumor mutation burden and BRAF V600 mutation. (PubMed, Front Oncol)

RFS and MSS were significantly improved in patients whose tumors had high TMB levels and BRAF V600E/K mutation (p<0.001 and p=0.002, respectively). Patients with BRAF-mutated tumors and high TMB seem to benefit particularly from adjuvant ICI.

3 months ago

Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker

BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden)

BRAF V600E • TMB-H • BRAF mutation • BRAF V600 • BRAF V600K

3ms

BRAF V600E Mutation Has Variable Tumor-Specific Effects on Expression of MAPK Pathway Genes That Could Affect Patient Outcome. (PubMed, Int J Mol Sci)

The MAPK pathway is differentially affected by the different cancers, with increased MAPK activation observed in melanoma and not in thyroid cancer. This may account in part for the observed differential response to BRAF inhibitors.

3 months ago

Journal

BRAF (B-raf proto-oncogene)

BRAF V600E • BRAF V600 • BRAF V600K • BRAF wild-type